Bioventus LLC, a med-tech company developing orthobiologics, is trying to raise $150 million through an IPO. As is typical of SEC filings when a company plans to go public, Bioventus' filing does note a number of risks it faces in the market. But one not-so-typical risk – which other companies wanting to go public in the future may also have to consider – is Brexit

This fall, patients with presbyopia are slated to have a new treatment option after the FDA gave a green light Wednesday to Lake Forest, Calif.-based Revision Optics' implantable Raindrop near vision inlay. It marks the first time the agency has approved a device that changes the shape of the cornea to improve vision.

Months after rebranding itself, Biostage Inc. is asking the FDA for orphan drug designation for its Cellspan esophageal implants, designed as an alternative to esophagectomy. CEO Jim McGorry said the company, which also is developing products for the bronchus and trachea, plans to file an IND application by the end of the year. "Assuming approval on a normal time frame, we believe that by this time next year our Cellspan esophageal implant should be in a human clinical pilot study," he told BioWorld Today.

Politicians and medical experts worldwide alike have decried the lack of innovation in antibiotics an area that has been neglected for three decades but another area is turning out to be just as important: diagnostics.

Politicians and medical experts worldwide alike have decried the lack of innovation in antibiotics – an area that has been neglected for three decades – but another area is turning out to be just as important: diagnostics.